Association between toll-like receptor expression and human papillomavirus type 16 persistence.
The mechanisms involved in mucosal immune control of cervical human papillomavirus (HPV) infection remain ill defined. Because toll-like receptors (TLRs) are key players in innate immune responses, we investigated the association between TLR expression and viral persistence or clearance in young women with incident infections with oncogenic HPV types 16 or 51. Messenger RNA expression of TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8 and TLR9 was measured by quantitative reverse transcription-PCR using human endocervical specimens, collected before and after viral acquisition, in a cohort well characterized for HPV infections. Wilcoxon rank sum test was used to compare the change seen from preinfection to incident infection between women who subsequently cleared infection with those who did not. HPV 16 infections that cleared were significantly (p < 0.05) associated with an increase in expression of the four viral nucleic acid-sensing TLRs (TLR3, TLR7, TLR8 and TLR9) as well as TLR2 upon viral acquisition. Similar associations were not observed for HPV 51. In women who subsequently cleared their HPV 16 infection, changes in TLR1, TLR3, TLR7 and TLR8 expression levels between preincident and incident visits were significantly correlated with parallel changes in the levels of interferon-α2, measured by immunoassay in cervical lavage specimens. This study suggests that dampened TLR expression in the cervical mucosa is a type-specific mechanism by which HPV 16 interferes with innate immune responses, contributing to viral persistence, and that TLR upregulation and resultant cytokine induction is important in subsequent viral clearance.
Daud
Ibrahim I
II
Infectious Disease Research Training Program, University of California, San Francisco, CA 94118, USA.
Scott
Mark E
ME
Ma
Yifei
Y
Shiboski
Stephen
S
Farhat
Sepideh
S
Moscicki
Anna-Barbara
AB
D000293:Adolescent; D000328:Adult; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007113:Immunity, Innate; D016898:Interferon-alpha / Q000378:metabolism; D030361:Papillomavirus Infections / Q000276:immunology / Q000378:metabolism* / Q000821:virology*; D011446:Prospective Studies; D012333:RNA, Messenger / Q000235:genetics; D012142:Respiratory Tract Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051193:Toll-Like Receptors / Q000378:metabolism*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D055815:Young Adult
D016898:Interferon-alpha; D012333:RNA, Messenger; D051193:Toll-Like Receptors
Curr Protoc Mol Biol. 2006 Feb;Chapter 15:Unit 15.8
18265376
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
12184808
Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34
16950015
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D684-8
16381959
Clin Diagn Lab Immunol. 1999 Sep;6(5):751-5
10473530
Nat Immunol. 2000 Nov;1(5):398-401
11062499
Virology. 2009 Feb 20;384(2):410-4
18986661
Gynecol Oncol. 2008 May;109(2 Suppl):S15-21
18474288
J Infect Dis. 2000 Aug;182(2):595-8
10915094
Int Immunol. 2005 Jan;17(1):1-14
15585605
J Infect Dis. 2000 Jun;181(6):1911-9
10837170
AIDS. 2007 Mar 12;21(5):589-98
17314521
J Allergy Clin Immunol. 2003 Feb;111(2):380-8
12589360
Clin Vaccine Immunol. 2008 Jan;15(1):49-54
17978011
J Leukoc Biol. 2007 Sep;82(3):479-87
17595379
Nat Rev Immunol. 2004 Apr;4(4):249-58
15057783
J Immunol. 2005 Jun 15;174(12):7912-9
15944297
Virology. 2005 Jun 20;337(1):76-84
15914222
Nucleic Acids Res. 2007 Jan;35(Database issue):D805-9
17068075
Immunology. 2006 Feb;117(2):220-8
16423058
J Immunol. 2007 Mar 1;178(5):3186-97
17312167
Clin Exp Dermatol. 2002 Oct;27(7):571-7
12464152
Cancer Res. 2004 Aug 15;64(16):5850-60
15313929
Blood. 2006 Jul 15;108(2):544-50
16537810
N Engl J Med. 2003 Feb 6;348(6):518-27
12571259
Front Biosci. 2002 Oct 01;7:d2058-71
12165480
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1315-20
14739339
J Virol. 2003 Apr;77(8):4588-96
12663765
Appl Environ Microbiol. 2007 Sep;73(18):5731-41
17644631
Clin Cancer Res. 2005 Jul 15;11(14):5273-80
16033846
Int J Gynecol Cancer. 2009 May;19(4):508-12
19509544
Clin Vaccine Immunol. 2008 Jun;15(6):937-45
18448624
Microbes Infect. 2004 Dec;6(15):1388-94
15596125
Semin Immunol. 2007 Feb;19(1):33-40
17336545
J Clin Immunol. 2006 May;26(3):222-32
16783462
J Virol. 2002 Sep;76(17):8729-36
12163593
J Pathol. 1999 Sep;189(1):12-9
10451482
Clin Vaccine Immunol. 2008 Sep;15(9):1369-73
18632922
J Natl Cancer Inst. 1995 Jun 7;87(11):796-802
7791229
J Pediatr. 1998 Feb;132(2):277-84
9506641
J Virol. 2006 May;80(9):4286-91
16611887
Vaccine. 2006 Mar 30;24 Suppl 1:S16-22
16219398